相似文献
1
Modeling therapy resistance via the EGFR signaling pathway.
FEBS J. 2019 Apr;286(7):1284-1286. doi: 10.1111/febs.14809. Epub 2019 Mar 20.
2
ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.
Clin Cancer Res. 2018 Aug 15;24(16):4044-4055. doi: 10.1158/1078-0432.CCR-17-3674. Epub 2018 May 14.
3
EGFR-TKIs resistance via EGFR-independent signaling pathways.
Mol Cancer. 2018 Feb 19;17(1):53. doi: 10.1186/s12943-018-0793-1.
4
EGFR-mediated autophagy in tumourigenesis and therapeutic resistance.
Cancer Lett. 2020 Jan 28;469:207-216. doi: 10.1016/j.canlet.2019.10.030. Epub 2019 Oct 19.
5
The quest to overcome resistance to EGFR-targeted therapies in cancer.
Nat Med. 2013 Nov;19(11):1389-400. doi: 10.1038/nm.3388. Epub 2013 Nov 7.
6
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
J Exp Clin Cancer Res. 2019 Jan 28;38(1):41. doi: 10.1186/s13046-019-1035-0.
7
Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Curr Cancer Drug Targets. 2010 Feb;10(1):68-79. doi: 10.2174/156800910790980205.
8
Predicting response to EGFR-tyrosine kinase inhibitors among diverse ancestries: just way too polymorphic.
Cancer Biol Ther. 2007 Jan;6(1):112-5. doi: 10.4161/cbt.6.1.3787.
9
Therapeutic targeting of the epidermal growth factor receptor in human cancer.
Crit Rev Oncog. 2012;17(1):31-50. doi: 10.1615/critrevoncog.v17.i1.40.
10
EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells.
Adv Cancer Res. 2020;147:161-188. doi: 10.1016/bs.acr.2020.04.003. Epub 2020 Jun 15.
引用本文的文献
1
Gnb5 is a negative regulator of the BACE1-mediated Aβ generation and ameliorates cognitive deficits in a mouse model of Alzheimer's disease.
PLoS Biol. 2025 Jun 30;23(6):e3003259. doi: 10.1371/journal.pbio.3003259. eCollection 2025 Jun.
2
Nucleic Acid Probes for Single-Molecule Localization Imaging of Cellular Biomolecules.
Chem Biomed Imaging. 2023 Apr 14;1(1):18-29. doi: 10.1021/cbmi.3c00012. eCollection 2023 Apr 24.
3
An evolutionary differential game for regulating the role of monoclonal antibodies in treating signalling pathways in oesophageal cancer.
R Soc Open Sci. 2024 Jul 31;11(7):240347. doi: 10.1098/rsos.240347. eCollection 2024 Jul.
4
A robust optimal control framework for controlling aberrant RTK signaling pathways in esophageal cancer.
J Math Biol. 2024 Jan 5;88(2):14. doi: 10.1007/s00285-023-02033-0.
5
The disruptor of telomeric silencing 1-like (DOT1L) promotes peritoneal fibrosis through the upregulation and activation of protein tyrosine kinases.
Mol Biomed. 2024 Jan 4;5(1):3. doi: 10.1186/s43556-023-00161-z.
6
Dietary Polyphenols against Oxidative Stress in Head and Neck Cancer: What's New, What's Next.
J Cancer. 2024 Jan 1;15(2):293-308. doi: 10.7150/jca.90545. eCollection 2024.
7
Cancer Therapeutic siRNA Delivery and Imaging by Nitrogen- and Neodymium-Doped Graphene Quantum Dots.
ACS Biomater Sci Eng. 2023 Jun 12;9(6):3425-3434. doi: 10.1021/acsbiomaterials.3c00369. Epub 2023 May 31.
本文引用的文献
1
Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cells.
FEBS J. 2019 Apr;286(7):1305-1318. doi: 10.1111/febs.14773. Epub 2019 Feb 20.
2
Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer.
Cancer Res. 2019 Feb 15;79(4):689-698. doi: 10.1158/0008-5472.CAN-18-1281. Epub 2019 Feb 4.
3
Drug Resistance Mechanisms in Colorectal Cancer Dissected with Cell Type-Specific Dynamic Logic Models.
Cancer Res. 2017 Jun 15;77(12):3364-3375. doi: 10.1158/0008-5472.CAN-17-0078. Epub 2017 Apr 5.
4
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer.
Oncotarget. 2017 Jan 17;8(3):3980-4000. doi: 10.18632/oncotarget.14012.
5
Phosphoproteome Profiling Reveals Molecular Mechanisms of Growth-Factor-Mediated Kinase Inhibitor Resistance in EGFR-Overexpressing Cancer Cells.
J Proteome Res. 2016 Dec 2;15(12):4490-4504. doi: 10.1021/acs.jproteome.6b00621. Epub 2016 Nov 16.
6
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.
Nat Med. 2016 Jun;22(6):624-31. doi: 10.1038/nm.4078. Epub 2016 May 2.
7
Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.
Elife. 2015 Aug 18;4:e04640. doi: 10.7554/eLife.04640.
8
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies.
J Mol Med (Berl). 2014 Jul;92(7):709-22. doi: 10.1007/s00109-014-1161-2. Epub 2014 May 10.
9
The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor.
J Mol Cell Biol. 2012 Jun;4(3):153-63. doi: 10.1093/jmcb/mjs021. Epub 2012 May 4.
10
Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy.
FEBS J. 2010 Jan;277(2):309-15. doi: 10.1111/j.1742-4658.2009.07449.x. Epub 2009 Nov 18.
Zotero 插件